Novel Anti-Infective Treatments

We are pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Our lead asset, ibrexafungerp (formerly known as SCY-078), is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class. On June 1, 2021, SCYNEXIS received regulatory approval for its first product from the U.S. Food and Drug Administration.

Learn More About Our Product
Ibrexafungerp: A Versatile Anti-Infective


Committed to Helping Patients Overcome and Prevent Difficult-to-Treat Infections

Our team strives to save and improve patients' lives by advancing a novel broad-spectrum antifungal therapy to address difficult-to-treat and often life-threatening infections, and to transforming the anti-infective treatment paradigms for patients worldwide.

More About Us

Our Innovative Antifungal Platform

Our lead asset, ibrexafungerp (formerly known as SCY-078), is an investigational antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, known as triterpenoids.

Our Science Our Pipeline

Success Backed by Strong Leadership

The innovation that drives our science and pipeline is a direct reflection of our leadership's commitment to bringing ibrexafungerp to patients in need, and ability to advance the product across multiple indications from discovery through to the commercial stage. This leadership has a proven track record and deep antifungal expertise needed to advance ibrexafungerp to commercialization.

Leadership Board of Directors



Nasdaq: SCYX



52-Week Range

Daily Volume

Day Range

Email Alerts

Receive the latest news directly to your inbox

Sign Up